These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 15548159)

  • 81. Antagonist/letrozole protocol in poor ovarian responders for intracytoplasmic sperm injection: a comparative study with the microdose flare-up protocol.
    Yarali H; Esinler I; Polat M; Bozdag G; Tiras B
    Fertil Steril; 2009 Jul; 92(1):231-5. PubMed ID: 18678368
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Viable pregnancy in a woman with premature ovarian failure treated with gonadotropin suppression and human menopausal gonadotropin stimulation. A case report.
    Check JH; Nowroozi K; Nazari A
    J Reprod Med; 1991 Mar; 36(3):195-7. PubMed ID: 1903165
    [TBL] [Abstract][Full Text] [Related]  

  • 83. To add GnRH antagonists to controlled ovarian stimulation in management of subfertile couples with IUI may not have additional effect in terms of clinical pregnancy rates.
    Kelekci S
    Fertil Steril; 2011 Aug; 96(2):e133; author reply e134. PubMed ID: 21669412
    [No Abstract]   [Full Text] [Related]  

  • 84. Can we skip weekends in GnRH antagonist cycles without compromising the final outcome?
    Bosch E
    Fertil Steril; 2012 Jun; 97(6):1299-300. PubMed ID: 22656307
    [No Abstract]   [Full Text] [Related]  

  • 85. Does thalassemia influence ovarian response? An analysis of 127 cycles involving pre-implantation genetic diagnosis of thalassemia in southern China.
    Yuan Y; Yuan X; Zhou C
    J Obstet Gynaecol; 2016 Aug; 36(6):778-782. PubMed ID: 27173414
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Pregnancy after ovarian superovulation by transdermal delivery of follicle-stimulating hormone.
    Zech NH; Murtinger M; Uher P
    Fertil Steril; 2011 Jun; 95(8):2784-5. PubMed ID: 21497348
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Use of hMG and/or FSH for multiple follicle development.
    Rosenwaks Z; Muasher SJ; Acosta AA
    Clin Obstet Gynecol; 1986 Mar; 29(1):148-57. PubMed ID: 3082552
    [No Abstract]   [Full Text] [Related]  

  • 88. Use of gonadotropic releasing hormone for ovulating the rabbit model.
    Foote RH; Simkin ME
    Lab Anim Sci; 1993 Aug; 43(4):383-5. PubMed ID: 8231104
    [No Abstract]   [Full Text] [Related]  

  • 89. The ultrashort flare GnRH-agonist/GnRH-antagonist protocol enables cycle programming and may overcome the "detrimental effect" of the oral contraceptive.
    Orvieto R
    Fertil Steril; 2012 Sep; 98(3):e17-8; author reply e19. PubMed ID: 22840381
    [No Abstract]   [Full Text] [Related]  

  • 90. [Ovulation induction with gonadotropin in patients with thalassemia pretreated with pulsatile GnRH: outcome].
    Vizziello G; Carone D; Caroppo E; Vitti A; Pasquadibisceglie A; D'Amato G
    Minerva Ginecol; 2004 Oct; 56(5):485-7. PubMed ID: 15531866
    [No Abstract]   [Full Text] [Related]  

  • 91. [Combined GnRH agonist/hMG therapy and ovarian overstimulation syndrome].
    Lindner C; Braendle W; Lichtenberg V; Bettendorf G
    Arch Gynecol Obstet; 1989; 245(1-4):860-1. PubMed ID: 2529827
    [No Abstract]   [Full Text] [Related]  

  • 92. [Is there a role for GnRH analogs in ovulation stimulation for in vitro fertilization?].
    Belaisch-Allart J; Mayenga JM
    Contracept Fertil Sex; 1998 Nov; 26(11):761-3. PubMed ID: 9864882
    [No Abstract]   [Full Text] [Related]  

  • 93. Multiple pregnancies in gonadotropin-stimulated cycles after human in vitro fertilization (IVF) and embryo replacement.
    Mettler L; Riedel HH; Bonhoff A; Michelmann HW
    Experientia; 1985 Dec; 41(12):1509-14. PubMed ID: 3935477
    [No Abstract]   [Full Text] [Related]  

  • 94. Progesterone administration route in gonadotropin-releasing hormone antagonist cycles.
    Bahceci M; Ulug U
    Fertil Steril; 2010 Aug; 94(3):e47; author reply e48. PubMed ID: 20627239
    [No Abstract]   [Full Text] [Related]  

  • 95. Pregnancies after IVF when high tonic LH is reduced by long-term treatment with GnRH agonists.
    Macnamee MC; Howles CM; Edwards RG
    Hum Reprod; 1987 Oct; 2(7):569-71. PubMed ID: 3119660
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Ovarian insufficiency (so called 'poor responder')].
    Ohba T; Okamura Y; Okamura H
    Nihon Rinsho; 2006 Jun; Suppl 2():356-60. PubMed ID: 16817421
    [No Abstract]   [Full Text] [Related]  

  • 97. Laboratory and embryological aspects of hCG-primed in vitro maturation cycles for patients with polycystic ovaries.
    Son WY; Tan SL
    Hum Reprod Update; 2010; 16(6):675-89. PubMed ID: 20504873
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Using a half dose of leuplin depot in a long-term protocol for in vitro fertilization.
    Tsai WK; Wu TP; Tsia HC; Huang YL; Wu IC
    Taiwan J Obstet Gynecol; 2012 Mar; 51(1):121-2. PubMed ID: 22482985
    [No Abstract]   [Full Text] [Related]  

  • 99. Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists.
    Ortmann O; Weiss JM; Diedrich K
    Hum Reprod; 2001 Apr; 16(4):608-11. PubMed ID: 11278203
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Basal serum pituitary hormone levels and outcome of in vitro fertilization utilizing a flare nasal gonadotropin releasing hormone agonist and fixed low-dose follicle-stimulating hormone/human menopausal gonadotropin regimen.
    Chan YF; Ho PC; So WW; Yeung WS
    J Assist Reprod Genet; 1993 May; 10(4):251-4. PubMed ID: 8130428
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.